Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy
Malignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades. However, the clinical management of melanoma is severely hampered by the absence of effective scree...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/902137 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567046061162496 |
|---|---|
| author | R. Ortenberg S. Sapoznik D. Zippel R. Shapira-Frommer O. Itzhaki A. Kubi D. Zikich M. J. Besser J. Schachter G. Markel |
| author_facet | R. Ortenberg S. Sapoznik D. Zippel R. Shapira-Frommer O. Itzhaki A. Kubi D. Zikich M. J. Besser J. Schachter G. Markel |
| author_sort | R. Ortenberg |
| collection | DOAJ |
| description | Malignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades. However, the clinical management of melanoma is severely hampered by the absence of effective screening tools. The expression of the CEACAM1 adhesion molecule on melanoma cells is a strong predictor of poor prognosis. Interestingly, a melanoma-secreted form of CEACAM1 (sCEACAM1) has recently emerged as a potential tumor biomarker. Here we add novel evidences supporting the prognostic role of serum CEACAM1 by using a mice xenograft model of human melanoma and showing a correlation between serum CEACAM1 and tumor burden. Moreover, we demonstrate that serum CEACAM1 is elevated over time in progressive melanoma patients who fail to respond to immunotherapy as opposed to responders and stable disease patients, thus proving a correlation between sCEACAM1, response to treatment, and clinical deterioration. |
| format | Article |
| id | doaj-art-9e9b459bbec340bbba9ef03b87f06a8f |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-9e9b459bbec340bbba9ef03b87f06a8f2025-02-03T01:02:33ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/902137902137Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer ImmunotherapyR. Ortenberg0S. Sapoznik1D. Zippel2R. Shapira-Frommer3O. Itzhaki4A. Kubi5D. Zikich6M. J. Besser7J. Schachter8G. Markel9The Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelThe Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, 52621 Tel Hashomer, IsraelMalignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades. However, the clinical management of melanoma is severely hampered by the absence of effective screening tools. The expression of the CEACAM1 adhesion molecule on melanoma cells is a strong predictor of poor prognosis. Interestingly, a melanoma-secreted form of CEACAM1 (sCEACAM1) has recently emerged as a potential tumor biomarker. Here we add novel evidences supporting the prognostic role of serum CEACAM1 by using a mice xenograft model of human melanoma and showing a correlation between serum CEACAM1 and tumor burden. Moreover, we demonstrate that serum CEACAM1 is elevated over time in progressive melanoma patients who fail to respond to immunotherapy as opposed to responders and stable disease patients, thus proving a correlation between sCEACAM1, response to treatment, and clinical deterioration.http://dx.doi.org/10.1155/2015/902137 |
| spellingShingle | R. Ortenberg S. Sapoznik D. Zippel R. Shapira-Frommer O. Itzhaki A. Kubi D. Zikich M. J. Besser J. Schachter G. Markel Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy Journal of Immunology Research |
| title | Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy |
| title_full | Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy |
| title_fullStr | Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy |
| title_full_unstemmed | Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy |
| title_short | Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy |
| title_sort | serum ceacam1 elevation correlates with melanoma progression and failure to respond to adoptive cell transfer immunotherapy |
| url | http://dx.doi.org/10.1155/2015/902137 |
| work_keys_str_mv | AT rortenberg serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT ssapoznik serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT dzippel serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT rshapirafrommer serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT oitzhaki serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT akubi serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT dzikich serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT mjbesser serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT jschachter serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy AT gmarkel serumceacam1elevationcorrelateswithmelanomaprogressionandfailuretorespondtoadoptivecelltransferimmunotherapy |